E
Eric J. Enemark
Federal Grant PI
High Impact
Associate Professor
faculty
Biochemistry & Molecular Biology, College of Medicine
21 h-index
76 pubs
2,650 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Eric J. Enemark, an Associate Professor in Biochemistry & Molecular Biology at the University of Arkansas for Medical Sciences, investigates the molecular mechanisms underlying nucleic acid machines. His research group focuses on the structural and functional characterization of proteins involved in DNA replication and viral RNA/ATP interactions. He is a Principal Investigator on a $380,002 NIH/National Institute of General Medical Sciences grant aimed at elucidating these molecular mechanisms.
Dr. Enemark's recent publications include studies on the ATP-binding and RNA-binding mechanisms of enteroviral 2C protein, the structural basis for DNA translocation by MCM helicases, and the functional impact of genetic variations in the HELB gene. He has also published work on the structure of the GINS tetramer from *Saccharolobus solfataricus*. His scholarly contributions are recognized by an h-index of 21, with over 75 publications and 2,630 citations. He collaborates with several researchers at the University of Arkansas for Medical Sciences, including Maroof K. Zafar, Alicia K. Byrd, Matthew D. Thompson, and Kirk L. West.
Metrics
- h-index: 21
- Publications: 76
- Citations: 2,650
Selected Publications
-
Rare SNP in the <i>HELB</i> gene interferes with RPA interaction and cellular function of HELB (2025)
-
Structure of the <i>Saccharolobus solfataricus</i> GINS tetramer (2025)
-
Rare SNP in the <i>HELB</i> gene interferes with RPA interaction and cellular function of HELB (2024)
-
Structural and functional characterization of Enteroviral 2C protein, an RNA-stimulated ATPase (2023)
-
Two Distinct Modes of DNA Binding by an MCM Helicase Enable DNA Translocation (2022)
-
Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP (2022)
-
Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP (2022)
-
Structure of a dimer of the <i>Sulfolobus solfataricus</i> MCM N-terminal domain reveals a potential role in MCM ring opening (2021)
Federal Grants 1 $380,002 total
NIH/National Institute of General Medical Sciences
Contact PI
Jun 2020 - May 2026
Collaboration Network
Top Collaborators
Sharyn D. Baker
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Eric I. Zimmerman
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Yong‐Dong Wang
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Shelley Orwick
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Douglas S. Zatechka
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Jassada Buaboonnam
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Geoffrey Neale
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Scott R. Olsen
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Sheila Shurtleff
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Jeffrey E. Rubnitz
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Charles G. Mullighan
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Hiroto Inaba
18 shared publications
- Supplementary Figure 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Methods from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 1 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 3 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
- Supplementary Table 2 from Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia
Showing 5 of 18 shared publications
Calvin Yeager
University of North Carolina at Chapel Hill (US)
4 shared publications
- Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Abstract 1245: Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Structural and functional characterization of Enteroviral 2C protein, an RNA-stimulated ATPase
David W. Gohara
Saint Louis University (US)
4 shared publications
- Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Abstract 1245: Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Structural and functional characterization of Enteroviral 2C protein, an RNA-stimulated ATPase
Neela H. Yennawar
Pennsylvania State University (US)
4 shared publications
- Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Abstract 1245: Enteroviral 2C protein is an RNA-stimulated ATPase and uses a two-step mechanism for binding to RNA and ATP
- Structural and functional characterization of Enteroviral 2C protein, an RNA-stimulated ATPase
Similar Researchers
Based on overlapping research topics
Cindi R. Browmiller
University of Arkansas at Fayetteville
Protein Structure and Dynamics
Molecular Biology Techniques and Applications
Viral Infections and Vectors
Thomas Augustine
University of Arkansas for Medical Sciences
Protein Structure and Dynamics
Molecular Biology Techniques and Applications
Viral Infections and Vectors
Vivek Govind Kumar
University of Arkansas at Fayetteville
Protein Structure and Dynamics
Molecular Biology Techniques and Applications
Viral Infections and Vectors
Stephanie Sauve
University of Arkansas at Fayetteville
Protein Structure and Dynamics
Molecular Biology Techniques and Applications
Viral Infections and Vectors
Sibes Bera
University of Arkansas for Medical Sciences
Protein Structure and Dynamics
Molecular Biology Techniques and Applications
Viral Infections and Vectors
Nathan Avaritt
University of Arkansas for Medical Sciences
Protein Structure and Dynamics
Molecular Biology Techniques and Applications
Viral Infections and Vectors